Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT
Cytomegalovirus (CMV) infection is a common, potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed prospectively the safety and efficacy of stem cell-donor- or third-party-donor-derived CMV-specific T cells for the treatment o...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
Leukemia
Year: 2017, Jahrgang: 31, Heft: 10, Pages: 2161-2171 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2017.16 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2017.16 Verlag, Volltext: https://www.nature.com/articles/leu201716 
|
| Verfasserangaben: | M. Neuenhahn, J. Albrecht, M. Odendahl, F. Schlott, G. Dössinger, M. Schiemann, S. Lakshmipathi, K. Martin, D. Bunjes, S. Harsdorf, E.M. Weissinger, H. Menzel, M. Verbeek, L. Uharek, N. Kröger, E. Wagner, G. Kobbe, T. Schroeder, M. Schmitt, G. Held, W. Herr, L. Germeroth, H. Bonig, T. Tonn, H. Einsele, D.H. Busch and G.U. Grigoleit |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576937984 | ||
| 003 | DE-627 | ||
| 005 | 20220814180420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180628s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/leu.2017.16 |2 doi | |
| 035 | |a (DE-627)1576937984 | ||
| 035 | |a (DE-576)506937984 | ||
| 035 | |a (DE-599)BSZ506937984 | ||
| 035 | |a (OCoLC)1341013061 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Neuenhahn, Michael |d 1975- |e VerfasserIn |0 (DE-588)12425196X |0 (DE-627)08573814X |0 (DE-576)294088709 |4 aut | |
| 245 | 1 | 0 | |a Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT |c M. Neuenhahn, J. Albrecht, M. Odendahl, F. Schlott, G. Dössinger, M. Schiemann, S. Lakshmipathi, K. Martin, D. Bunjes, S. Harsdorf, E.M. Weissinger, H. Menzel, M. Verbeek, L. Uharek, N. Kröger, E. Wagner, G. Kobbe, T. Schroeder, M. Schmitt, G. Held, W. Herr, L. Germeroth, H. Bonig, T. Tonn, H. Einsele, D.H. Busch and G.U. Grigoleit |
| 264 | 1 | |c 2017 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Advance online publication, 17 February 2017 | ||
| 500 | |a Gesehen am 28.06.2018 | ||
| 520 | |a Cytomegalovirus (CMV) infection is a common, potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed prospectively the safety and efficacy of stem cell-donor- or third-party-donor-derived CMV-specific T cells for the treatment of persistent CMV infections after allo-HSCT in a phase I/IIa trial. Allo-HSCT patients with drug-refractory CMV infection and lacking virus-specific T cells were treated with a single dose of ex vivo major histocompatibility complex-Streptamer-isolated CMV epitope-specific donor T cells. Forty-four allo-HSCT patients receiving a T-cell-replete (D+ repl; n=28) or T-cell-depleted (D+ depl; n=16) graft from a CMV-seropositive donor were screened for CMV-specific T-cell immunity. Eight D+ depl recipients received adoptive T-cell therapy from their stem cell donor. CMV epitope-specific T cells were well supported and became detectable in all treated patients. Complete and partial virological response rates were 62.5% and 25%, respectively. Owing to longsome third-party donor (TPD) identification, only 8 of the 57 CMV patients transplanted from CMV-seronegative donors (D−) received antigen-specific T cells from partially human leukocyte antigen (HLA)-matched TPDs. In all but one, TPD-derived CMV-specific T cells remained undetectable. In summary, adoptive transfer correlated with functional virus-specific T-cell reconstitution in D+ depl patients. Suboptimal HLA match may counteract expansion of TPD-derived virus-specific T cells in D− patients. | ||
| 700 | 1 | |a Schmitt, Michael |d 1966- |e VerfasserIn |0 (DE-588)133177173 |0 (DE-627)538000600 |0 (DE-576)299672921 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 31(2017), 10, Seite 2161-2171 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT |
| 773 | 1 | 8 | |g volume:31 |g year:2017 |g number:10 |g pages:2161-2171 |g extent:11 |a Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/leu.2017.16 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/leu201716 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180628 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 133177173 |a Schmitt, Michael |m 133177173:Schmitt, Michael |d 910000 |d 910100 |e 910000PS133177173 |e 910100PS133177173 |k 0/910000/ |k 1/910000/910100/ |p 19 | ||
| 999 | |a KXP-PPN1576937984 |e 3014620475 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Neuenhahn, Michael","family":"Neuenhahn","role":"aut","roleDisplay":"VerfasserIn","given":"Michael"},{"given":"Michael","roleDisplay":"VerfasserIn","role":"aut","display":"Schmitt, Michael","family":"Schmitt"}],"title":[{"title_sort":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT"}],"physDesc":[{"extent":"11 S."}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"1576937984","name":{"displayForm":["M. Neuenhahn, J. Albrecht, M. Odendahl, F. Schlott, G. Dössinger, M. Schiemann, S. Lakshmipathi, K. Martin, D. Bunjes, S. Harsdorf, E.M. Weissinger, H. Menzel, M. Verbeek, L. Uharek, N. Kröger, E. Wagner, G. Kobbe, T. Schroeder, M. Schmitt, G. Held, W. Herr, L. Germeroth, H. Bonig, T. Tonn, H. Einsele, D.H. Busch and G.U. Grigoleit"]},"relHost":[{"recId":"32046699X","note":["Gesehen am 15.03.04"],"id":{"eki":["32046699X"],"zdb":["2008023-2"],"issn":["1476-5551"]},"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCTLeukemia","language":["eng"],"part":{"text":"31(2017), 10, Seite 2161-2171","pages":"2161-2171","issue":"10","extent":"11","year":"2017","volume":"31"},"pubHistory":["Nachgewiesen 11.1997 -"],"title":[{"subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title":"Leukemia","title_sort":"Leukemia"}],"origin":[{"dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedKey":"1997"}]}],"id":{"eki":["1576937984"],"doi":["10.1038/leu.2017.16"]},"note":["Advance online publication, 17 February 2017","Gesehen am 28.06.2018"]} | ||
| SRT | |a NEUENHAHNMTRANSFEROF2017 | ||